First human tests begin for new ALS drug candidate
NCT ID NCT07221240
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called amisodin in 48 healthy adults to see if it is safe and how the body processes it. The study is a first step before testing the drug in people with ALS. Participants receive either the drug or a placebo, and researchers monitor for side effects and measure drug levels in the blood.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pharmaron, Inc.
RECRUITINGBaltimore, Maryland, 21201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new rowing seat help veterans with paralysis row freely?
- Can filtering the blood slow ALS in patients with a rogue antibody?
- Custom-Made genetic drug takes aim at rare form of ALS
- Tailored genetic drug takes aim at a rare form of ALS
- Custom-Made genetic drug takes aim at rare form of ALS
- Spinal cord cell transplant aims to slow ALS